Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.

about

Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis Visual Hallucinations and Amyloid Deposition in Parkinson's Disease Dementia: A Case Report.

P2860

Q28074468-47196699-E674-4911-BC1A-4EBCED22C369 Q36932291-37E9DD8B-EB82-416E-AD1E-B675FDB939CB

P2860

Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.

Item

http://www.wikidata.org/entity/Q38258699

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.

@en

type

Item

label

Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.

@en

prefLabel

Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.

@en

P1476

Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.

@en

P2093

Anne Corbett

http://www.w3.org/2001/XMLSchema#string

Martin Broadstock

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacology of hallucinations: several mechanisms for one single symptom?

Staging of brain pathology related to sporadic Parkinson's disease

Melperone is ineffective in treating Parkinson's disease psychosis

The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.

The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria.

Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.

P304

779-786

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17512433.2014.966814

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Clive Ballard

P577

2014-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25301532

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

psychosis

Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.

about

P2860

P2860

Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921